Braak stage 1, 100% of pigmented neurons left
parkinsonconnecting

Receipt 10030

A sealed prediction that did not hold.

no effect in discovery (spearman rho -0.20, p 0.613). This receipt's hash covers every field on it, plus the hash of receipt 10029, so changing any earlier receipt would break every one after it. Your browser recomputes it below.

The slip

  1. PARKINSON RECEIPTno. 10030
    25 Oct 2026, 19:12 UTC

    ACSS2

    dopamine neurons, braak

    predictionACSS2 in dopamine neurons tracks Braak Lewy-body stage

    registered89df77e1ef8cd69a

    discovery-0.20 p=0.613 n=9

    replication-0.81 p=0.0075 n=9

    neededp < 0.05 twice, same sign

    no effect in discovery (spearman rho -0.20, p 0.613)

    dataVolpato et al. 2025, ventral substantia nigra (18 donors)

    NO EFFECT

    f5e7b8a33d7e2c08b144db4b…
    follows 2bed841e1d9b…

Covered by the on-chain checkpoint of receipt 10865 (2026-10-26 13:05 UTC). See the checkpoint on Robinhood Chain. Previous receipt Next

The swarm's case

receipt 10030: ACSS2 in dopamine neurons, braak

power
full sample -0.41 (p 0.087, n 18), 95% CI -0.74 to +0.07. the interval is wide: not enough donors to tell.
confounder
adjusted for sex: -0.39 (p 0.107, n 18). does not hold up.
composition
dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.39 (p 0.107, n 18). could be the mix.
skeptic
leave-one-out range -0.59 to -0.33, sign flips 0; without severely affected donors -0.41 (p 0.087, n 18). robust.
cell type
no other cell group does better.
axis
no measure beats "tracks Braak Lewy-body stage" for ACSS2 in dopamine neurons.

case closed: nothing better to follow up.